SOFINNOVA
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx. USD 112 million) Series B financing round. Sofinnova co-founded and seed financed Noema in 2019 with Dr. George Garibaldi and Luigi Costa. The company was established to advance clinical stage assets in-licensed from Roche.
Noema is a clinical-stage biopharmaceutical company focused on central nervous system disorders. Existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus welcomed new investors Forbion and Jeito Capital, as well as UPMC Enterprises and another undisclosed investor.
The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets, including its lead compound basimglurant (NOE-101), an mGluR5 inhibitor that is being evaluated in Phase 2b clinical trials for severe pain in Trigeminal Neuralgia (TN) and seizures in Tuberous Sclerosis Complex (TSC). The company is also developing gemlopodect (NOE-105), a PDE10a inhibitor being evaluated in Phase 2b clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder (COFD) or Stuttering; and NOE-115, a Phase 2 ready triple reuptake inhibitor for Atypical Depression and Binge Eating Disorder.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “As co-founders and initial investors of Noema, we are incredibly proud of what the company has accomplished since its inception. Raising an oversubscribed funding round of this magnitude is a significant achievement that further reinforces our conviction that Noema can make a meaningful difference in the lives of patients suffering from debilitating CNS disorders. Noema is the perfect illustration of our core strategy and expertise: we nurture innovative companies centered on groundbreaking science and exceptional talent that have the potential to deliver transformative results for patients.”
Luigi Costa, Chief Executive Officer of Noema Pharma, said: "We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”
The Series B financing follows a CHF 54 million (approx. USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners. Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
About Noema Pharma
Noema Pharma (www.noemapharma.com) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005296/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Resolves Multi-Year Patent Infringement Litigation With SMA13.5.2025 15:00:00 CEST | Press release
Settlement validates Tigo Intellectual Property, concludes IP litigation with SMA, and reinforces innovation in the marketplace. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that it has reached a multi-year settlement with SMA (SMA Solar Technology AG and SMA Solar Technology America LLC) over litigation regarding the infringement of Tigo intellectual property by SMA. The settlement concludes the infringement complaint brought by Tigo on July 11, 2022, Case No. 1:22-cv-00915 (D. Del.) alleging infringement of certain patents by SMA. Terms of the settlement will remain undisclosed. According to National Electric Code § 690.12, “Rapid Shutdown of PV Systems on Buildings” requires that PV system circuits “installed on or in buildings shall include a rapid shutdown function to reduce shock hazard for emergency responders.” Tigo rapid shutdown technology is compliant with UL 1741, the Standard
GPs Rethink Operational Tactics Amid Rising SPV Complexity13.5.2025 15:00:00 CEST | Press release
Nearly three quarters of GPs cite growing regulatory burdens as a top risk LP demand accelerates shift to co-investment, sector-specific, and evergreen structures63% of GPs scale outsourcing to enhance efficiency and drive growth Faced with rising regulatory demands and operational pressures, general partners (GPs) are increasingly turning to outsourcing and technology to manage special purpose vehicles (SPVs) more efficiently. This trend is highlighted in a new report from CSC, the leading provider of global business administration and compliance solutions. CSC surveyed 400 GPs across the Americas, Europe (including the U.K.), and Asia Pacific to uncover how today’s market shifts and operational pressures are reshaping SPV management strategies.1 The full findings are detailed in the report SPV Global Outlook 2025: How GPs are Shaping Strategies for Long-Term Success. Regulatory compliance and risk mitigation are firmly at the top of GPs’ agendas, with nearly three-quarters identifyin
Boomi Announces FY25 EMEA Partner Award Winners13.5.2025 15:00:00 CEST | Press release
Boomi™, the leader in AI-driven automation, announced today the winners of its FY25 Europe, Middle East, and Africa (EMEA) Partner Awards - recognized at the 2025 Boomi Partner Summit held in Dallas, Texas. The awards recognize innovative partner organizations across the region that have harnessed the power of the Boomi Enterprise Platform to deliver outstanding customer outcomes, accelerate digital transformation, and build scalable, AI-ready data ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513864198/en/ Boomi Announces FY25 EMEA Partner Award Winners Award winners were selected based on their ability to creatively solve complex business challenges, deliver measurable impact, and champion sustainable, forward-looking solutions for customers leveraging the Boomi platform’s end-to-end capabilities. “Across EMEA, organizations are under immense pressure to automate, integrate, and innovate — all while prepari
1GLOBAL Enables N26 to Become Germany’s first Digital Bank to offer eSIM Mobile Plans13.5.2025 14:30:00 CEST | Press release
In a move set to reshape the intersection of fintech and telecom, 1GLOBAL, a technology-driven global mobile communications provider, has teamed up with N26 to enable it to become the first digital bank in Germany to offer local mobile plans. This partnership will grant N26’s German customers seamless access to flexible, affordable, and contract-free mobile connectivity—all activated directly through the N26 app. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513954446/en/ 1GLOBAL, a technology-driven global mobile communications provider, has teamed up with N26 to enable it to become the first digital bank in Germany to offer local mobile plans. By integrating 1GLOBAL’s cutting-edge API, N26 has unlocked a frictionless mobile experience that eliminates the need for physical SIM cards, lengthy contracts, or cumbersome paperwork. Customers can activate their mobile plans in a few taps, enjoying instant connectivity that mi
Novotech Wins Citeline CRO Partnership of the Year Award for Strategic Collaboration with Tune Therapeutics13.5.2025 14:05:00 CEST | Press release
Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics, a pioneering epigenetic editing company. This honor celebrates the teams’ partnership and sets a benchmark for CRO–biotech partnerships. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513574699/en/ Novotech is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics. The CRO Partnership of the Year award honors outstanding collaboration between a CRO and a pharmaceutical or biotech company that has advanced clinical programs through strong alignment and shared goals. Sarah Anderson, Director of Therapeutic Strategy, and Steve Roan, Associate Director of Business Development, acce
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom